Pharsight

Complera generic

Complera is an antiretroviral medication used for the treatment of HIV infection. It contains three active ingredients: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil Fumarate. Manufactured by Gilead Sciences Inc., Complera was first authorized for market use on 10th August, 2011. The drug has a total of 9 patents, out of which 2 have already expired.

When will Complera generic be available?

The generic version of Complera is projected to become available after 14th January, 2033. This release date takes into account the expiry date of the last patent related to Complera, which is due to expire on this date.

Complera uses

Complera is used to treat HIV infection. Its three active ingredients work together to inhibit the replication of the virus in the body: Emtricitabine and Tenofovir Disoproxil Fumarate are nucleoside reverse transcriptase inhibitors that block a vital virus enzyme, and Rilpivirine Hydrochloride is a non-nucleoside reverse transcriptase inhibitor that binds to and alters this enzyme.

Complera patent expiration

Complera holds a total of 9 patents, with the latest patent set to expire on 14th January, 2033. Two of these patents have already expired. The remaining patents cover various aspects of the formulation and use of the drug. To learn more about when the Complera generic will be available, refer to the details of the patents below:

EPO Oppostions filed on Complera

Complera dosage

Want to ask something?